According to The Fly, aurinia Pharma (AUP), the Healthcare company, has received a rating update from a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright rated Aurinia Pharma (AUP) a Buy.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 8.5% and a 37.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Melinta Therapeutics Inc, and Collegium Pharmaceutical.
Read also: MYOS RENS Technology (MYOS) Stock Fires Up to the Roof; Here’s Why
Aurinia Pharma has an analyst consensus of Moderate Buy.
Aurinia Pharma’s market cap is currently C$692.8M and has a P/E ratio of 0. The company has a Price to Book ratio of 4.28.
Aurinia Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
The company’s shares closed on Thursday at C$8.12.
